Skip to content
DataLookout
Menu

NCT07927998

A Study of Retifanlimab After Chemoradiation in People With Anal Cancer

StatusRecruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Rate of ctDNA clearance at 12 weeks
Timeframe: 12 weeks

Arms and interventions

Anal squamous cell carcinomaExperimental

Participants have pathologically confirmed anal squamous cell carcinoma

Drugs: Retifanlimab

Sites

7 sites in 1 country